Itraconazole versus ketoconazole in the treatment of tinea versicolor

References

• Al-Sogair S, Al-Humaiden Y, Moawad M. Versicolor in the eastern province of Saudi Arabia. Ann Saudi Med 1989; 9: 449–552
   Google Scholar
• Hay R, Robert S, Mackenzie D. Mycology. Textbook of dermatology, 5th edn., A. D Rook Wilkinson, F Ebling. Blackwell Scientific, London 1992; 1127
   Google Scholar
• Svejgaard E. Oral ketoconazole as an alternative to gri-seofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Derm Venereol 1985; 65(2)143–9
   PubMedGoogle Scholar
• Rausch L J, Jacobs P H. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984; 34(5)470–1
   PubMed Web of Science ®Google Scholar
• Alteras I, Sandbank M, Segal R. Two years of follow-up of oral ketoconazole therapy in 60 cases of pityriasis versicolor. Dermatologica 1987; 175(3)142–4
   PubMedGoogle Scholar
• Haneke E. Retention of ketoconazole in the skin following oral treatment. Hautarzt 1987; 38(2)93–6
   PubMedGoogle Scholar
• Schewach-Millet M, Kahana M, Levy A, et al. Ketoconazole - an effective treatment for disseminated pityriasis versicolor. Isr J Med Sci 1984; 20(5)417–19
   PubMedGoogle Scholar
• Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987; 9(Suppl 1)S43–6
   PubMedGoogle Scholar
• Heeres J, Backx L J, Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem 1984; 27(7)894–900
   PubMedGoogle Scholar
• Van Cutsem J., Gerven F, Janssen P A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987; 9(Suppl 1)S15–32
   Google Scholar
• Bailey E M, Krakovsky D J, Rybak M J. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990; 10(2)146–53
   PubMedGoogle Scholar
• Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36(4)423–6
   PubMed Web of Science ®Google Scholar
• Grant S M, Clissold S P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37(3)310–44
   PubMedGoogle Scholar
• Wishart J M. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 1987; 17(2 Pt 1)220–3
   PubMedGoogle Scholar
• Cleary J D., Taylor J W, Chapman S W. Itraconazole in antifungal therapy. Ann Pharmacother 1992; 26(4)502–9
   PubMed Web of Science ®Google Scholar
• Graybill J R. New antifungal agents. Eur J Clin Microbiol Infect Dis 1989; 8(5)402–12
   PubMedGoogle Scholar
• Cauwenbergh G, De Doncker P, Stoops K, et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987; 9(Suppl 1)S146–52
   Google Scholar
• Larosa E, Cauwenbergh G, Cilli P, et al. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol 1986; 23(1–2)85–9
   PubMedGoogle Scholar
• Heykants J, Michiels M, Meuldermans W, . Development and evaluation of antifungal agents. Recent trends in the discovery, development and evaluation of antifungal agents, R Fromtling, et al. JR Prous Science Publishers, Barcelona 1987; 223–49
   Google Scholar
• Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990; 23(3 Pt 2)554–8
   PubMedGoogle Scholar
• Willemsen M. New therapeutic concepts in onychomycosis. J Eur Acad Dermatol Venereol 1991; l(Suppl)S21–S25
   Google Scholar
• Elewski B E. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28(5 Pt 1)S28–S34
   PubMed Web of Science ®Google Scholar
• Strippoli V, Piacentini A, D'Auria F D, Simonetti N. Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo. Infection 1997; 25(5)303–6
   PubMedGoogle Scholar
• Borelli D, Jacobs P H, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol 1991; 25(2 Pt 1)300–5
   PubMedGoogle Scholar
• Van Tyle J H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 1984; 4(6)343–73
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. Ann Intern Med 1985; 103(6 Ptl)861–72
   PubMedGoogle Scholar
• Heel R C, Brogden R N, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982; 23(1–2)1–36
   PubMed Web of Science ®Google Scholar
• Schafer-Korting M, Korting H C, Dorn M, Mutschler E. Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol 1984; 22(7)371–4
   PubMedGoogle Scholar
• Harris R, Jones H E, Artis W M. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 1983; 24(6)876–82
   PubMed Web of Science ®Google Scholar
• Schmidt A, Ruhl-Horster B. In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses 1996; 39(7–8)309–12
   PubMedGoogle Scholar
• Fernandez-Nava H D, Laya-Cuadra B, Tianco E A. Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor [see comments]. Int J Dermatol 1997; 36(1)64–6
   PubMedGoogle Scholar